Antibody and cell-mediated immune responses are correlates of protection against influenza infection in vaccinated older adults

Chris P. Verschoor, Melissa K. Andrew, Mark Loeb, Graham Pawelec, Laura Haynes, George A. Kuchel, Janet E. McElhaney

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

10 Citas (Scopus)

Resumen

Despite efforts to design better vaccines for older adults, the risk for serious complications of influenza remains disproportionately high. Identifying correlates of vaccine effectiveness and understanding the heterogeneity of health outcomes in older adults are key to the vaccine development pipeline. We sought correlates of protection against laboratory-confirmed influenza illness (LCII) in a 4-year randomized trial of standard versus high-dose influenza vaccination of adults 65 years and older. To this end, we quantified serum hemagglutination-inhibition (HAI) titers and interferon-gamma (IFNγ) and interleukin-10 (IL-10) secretion by virus-challenged peripheral blood mononuclear cells. Of the 608 participants included, 26 developed either A/H3N2-(n = 17) or B-LCII (n = 9) at 10–20 weeks post-vaccination. Antibody titres for A/H3N2 at 4-weeks post-vaccination were significantly associated with protection against LCII, where every 1-standard deviation increase reduced the odds of A/H3N2-LCII by 53%. Although B-titres did not correlate with protection against B-LCII, the fold-increase in IFNγ:IL-10 ratios from pre-to 4-weeks post-vaccination was significantly associated with protection against B-LCII, where every 1-standard deviation increase reduced the odds by 71%. Our results suggest that both antibody and cell-mediated immune measures are valuable and potentially complementary correlates of protection against LCII in vaccinated older adults, although this may depend on the viral type causing infection.

Idioma originalEnglish
Número de artículo25
Páginas (desde-hasta)1-12
Número de páginas12
PublicaciónVaccines
Volumen9
N.º1
DOI
EstadoPublished - ene. 2021

Nota bibliográfica

Funding Information:
Conflicts of Interest: J.E.M. reports payments to her institution for her participation in advisory, scientific, or data safety and monitoring boards from Sanofi, G.S.K., Pfizer, Merck, ResTORbio, and Medicago, and as a site lead clinical trials sponsored by VBI and Jansen, outside the submitted work. L.H. reports payments from Spring Discovery for her work in an advisory capacity. M.L. reports grant funding, in-kind supply of vaccines, or honoraria for participation in advisory boards, from Seqirus, Sanofi, Medicago, and Pfizer. M.K.A. reports payments from GSK (grant funding), Sanofi (grants, honoraria and consulting fees) and Pfizer (grants and honoraria), outside the submitted work. G.A.K. reports grants from the US National Institutes of Health and honoraria for participation in advisory boards from ResTORbio, Janssen and Spring Discovery. C.P.V. and G.P. report no conflicts of interest. The funders had no role in the design of the study, collection, analyses, or interpretation of data, the writing of the manuscript, or in the decision to publish the results.

Funding Information:
Funding: We would like to acknowledge the generous funding provided by the NIA/National Institutes of Health to Kuchel and McElhaney and co-investigators (R01 AG048023). McElhaney is supported by the Health Sciences North Research Chair in Healthy Aging and Kuchel is supported by the Travelers Chair in Geriatrics and Gerontology.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.

ASJC Scopus Subject Areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

PubMed: MeSH publication types

  • Journal Article

Huella

Profundice en los temas de investigación de 'Antibody and cell-mediated immune responses are correlates of protection against influenza infection in vaccinated older adults'. En conjunto forman una huella única.

Citar esto